ZY19489 + Ferroquine (FQ) + Placebo
Phase 1Recruiting 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Uncomplicated Malaria
Conditions
Uncomplicated Malaria, Asymptomatic Condition, Falciparum Malaria
Trial Timeline
Aug 30, 2024 → May 30, 2025
NCT ID
NCT05911828About ZY19489 + Ferroquine (FQ) + Placebo
ZY19489 + Ferroquine (FQ) + Placebo is a phase 1 stage product being developed by Zydus Lifesciences for Uncomplicated Malaria. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05911828. Target conditions include Uncomplicated Malaria, Asymptomatic Condition, Falciparum Malaria.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05911828 | Phase 1 | Recruiting |
Competing Products
13 competing products in Uncomplicated Malaria
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| KLU156 + Coartem | Novartis | Phase 3 | 77 |
| Artemether-lumefantrine (COA566) | Novartis | Phase 2/3 | 65 |
| INE963 | Novartis | Phase 2 | 52 |
| KAE609 + SoC (Coartem) + KLU156 | Novartis | Phase 2 | 52 |
| KAF156 + Coartem + Lumefantrine Solid Dispersion Formulation | Novartis | Phase 2 | 52 |
| INE963 + KAE609 (Cipargamin) + SoC (Coartem) + KLU156 | Novartis | Phase 2 | 52 |
| KAF156 + LUM-SDF + Coartem | Novartis | Phase 2 | 52 |
| Co-artemether | Novartis | Approved | 85 |
| Broncho-munal® + Placebo | Sandoz Group | Phase 3 | 74 |
| Placebo of Phenazopyridine Hydrochloride Tables, USP 200 mg + Phenazopyridine Hydrochloride Tables, USP 200 mg | Amneal Pharmaceuticals | Phase 3 | 72 |
| Peramivir + Placebo | BioCryst Pharmaceuticals | Phase 2 | 47 |
| solithromycin + ceftriaxone + azithromycin | Allergy Therapeutics | Phase 3 | 72 |
| Sulopenem-Etzadroxil/Probenecid + Ciprofloxacin | Iterum Therapeutics | Phase 3 | 69 |